FDA Approves ROTARIX(R) Rotavirus Vaccine

AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced that its partner, GlaxoSmithKline (GSK), has received approval from the U.S. Food and Drug Administration (FDA) for ROTARIX® for the prevention of rotavirus gastroenteritis in infants. With only two doses, ROTARIX will offer protection against the most commonly circulating rotavirus types in the U.S. and allow infants to complete the vaccination series by four months of age. The U.S.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 8th, 2008